Pre-prototype · Simulation-validated

Real-time guidance to a target that won't hold still.

SyncAblate gives the clinician live, directional guidance toward a respiratory-moving target — advance, hold, or adjust — and confirms the moment alignment is right before each move.

Liver & lung · biopsy and ablation · the clinician stays in control

SyncAblate · Concept Visualisation GUIDING
HOLD
NEEDLE · APPROACHING
Hold Adjust Prepare Advance
TARGET RESPIRATORY GUIDANCE REAL-TIME CLINICIAN IN CONTROL
The Clinical Problem

The target won't hold still — and there's no signal for how or when to move.

In CT-guided liver and lung procedures, the clinician steers a needle toward a target that moves with every breath — judging direction and timing by eye and experience alone.

01

The target moves with every breath

A liver or lung target can travel well over a centimetre with normal breathing — and substantially more under deeper breaths. A few millimetres is the difference between a clean sample and a missed one.

02

Surface sensors track a proxy

Respiratory belts and external markers measure chest-wall movement — a stand-in for the target, not the target itself. The relationship between the two is not fixed.

03

Direction and timing are guesswork

Whether the needle is on-line, and whether this is the moment to advance, are judged in real time by eye. The aligned window can last a fraction of a second.

The Approach

Track. Predict. Guide.

SyncAblate adds one missing layer: clear, real-time guidance toward the target — advance, hold, or adjust — confirmed safe before each move. It does not replace the clinician, the CT, or the ultrasound, and it never moves the needle.

STEP 01

Track

The system follows the target's motion in real time, rather than inferring it from the body surface.

STEP 02

Predict

It forecasts where the target will be roughly 200 milliseconds ahead, so guidance accounts for human reaction delay.

STEP 03

Guide

It turns that into a clear, real-time command — advance, hold, or adjust — and confirms alignment is safe before ever signalling advance. The guidance is the heart of it; the timing is what keeps it safe.

Architecture and safety-logic detail are held confidentially and protected under filed patents — this page describes the concept only.

SyncAblate doesn't replace the clinician's hands — it guides them. Live, directional guidance to a moving target: advance, hold, adjust — confirmed at the moment alignment is right.

The clinician decides · the system advises · it fails safe
Latest News

Recent milestones.

May 2026 Recognition

Semi-finalist — 2026 Australian Technologies Competition

SyncAblate has been selected as a semi-finalist in the 2026 Australian Technologies Competition, in the MedTech & Pharma — Biotech, Device & Other category, from a field of more than 200 applications.

June 2026 Upcoming

Invited to present to the UNSW IHealthE expert panel

SyncAblate has been invited to present to the University of New South Wales IHealthE expert panel — bringing clinical, engineering, and regulatory perspectives together in one room.

Where The Project Stands

Honest about the stage. Serious about the path.

Every figure below comes from computational simulation against published respiratory-motion data. The next step is a physical bench prototype.

4
Provisional patents filed with IP Australia
200ms
Predictive horizon — designed to offset clinician reaction time
10k
Breathing cycles in the locked verification simulation
IEC 62304
Software written to the medical-device software standard (Class C)

Pre-prototype. Simulation-validated. No patient data. SyncAblate has not been built as a physical device and has not been used in any clinical procedure. All performance characteristics are derived from simulation and establish mathematical feasibility only — they are not clinical claims.

Who We're Talking To

An enabling technology — built to integrate, not compete.

Interventional Radiologists

Clinical validation of the workflow and the value of real-time directional guidance at the point of commitment.

Device Manufacturers

A guidance-and-safety layer designed to integrate with existing needle and ablation platforms.

Research Partners

Bench validation, motion-platform access, and the path from simulation to physical evidence.

Investors

An IP-protected concept at the pre-prototype stage with a defined route to first bench data.

Get In Touch

Request the technical briefing

Detailed materials are shared under a confidentiality agreement. If you're a clinician, manufacturer, research partner, or investor, get in touch to start the conversation.

Contact Frank Mirabito →
frank@syncablate.com · Sydney, Australia